Feb 02, 2023 / 05:30PM GMT
James Sapirstein - First Wave BioPharma, Inc. - Chairman, President, CEO
Hello. My name is James Sapirstein. I'm the Chairman, President, and CEO of First Wave BioPharma. We are a gastroenterology clinical-stage biotech company. And thank you attending my presentation.
This is your normal company disclaimer. You may hear some things that I say, which have been presented before, but we will be -- I'll only talk about public information.
So the company really has two Phase 2-ready assets or clinical assets. The first one is adrulipase. Adrulipase is a recombinant enzyme. It's a lipase biological for treatment of exocrine pancreatic disorder, both in the pancreatitis and cystic fibrosis patients. And niclosamide, which has been around for a very long time, but it's a repurposed small molecule with -- which has a very potent anti-inflammatory profile. And we have a proprietary micronized formulation.
We'll talk a little bit about both products, but suffice to say, with niclosamide, due to resource constraints, we've had to put some things on hold there. We have a terrific IP in
First Wave BioPharma Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Feb 02, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers